Difference between revisions of "Meindl-Beinker NM, et al. BMC Cancer (2019) cited as Ref 636 in DOI: 10.1038/s41392-020-0110-5 (Q9899)"
Jump to navigation
Jump to search
(Created claim: PubMed ID (P140): 30871493, #quickstatements; #temporary_batch_1590001671040) |
(Created claim: Page(s) (P105): 231-, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (4 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2019
| ||||||||||||||
| Property / Publication Date: 2019 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | BMC Cancer | ||||||||||||||
| Property / Published In Name String: BMC Cancer / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 19 | ||||||||||||||
| Property / Volume: 19 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) (English) | ||||||||||||||
| Property / title: A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 231- | ||||||||||||||
| Property / Page(s): 231- / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Meindl-Beinker NM, et al. BMC Cancer (2019) cited as Ref 636 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Meindl-Beinker NM
0 references
2019
0 references
BMC Cancer
0 references
19
0 references
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) (English)
0 references
231-
0 references
